DV
Dividend Vision

PMN — ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. (PMN)

Total return is 1288.8% over the past 20.4 years, 524.1 points ahead of SPY at 764.7%. Its deepest 1-year drawdown was 63.2%.

ProMIS Neurosciences is a Canadian biopharmaceutical company that discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases caused by misfolded proteins, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company does not currently distribute dividends. ProMIS appeals to investors seeking exposure to early-stage biotechnology development rather than current income.

PMN key facts

Asset type
Stock
Asset class
Equity
Inception date
03/15/2006
Last close
$14.86
Market cap
$135,187,968
Average volume
29800.0
Beta
-0.211
Payout ratio
0.0
Forward P/E
0.0
EPS
$-17.99